| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | ERAS | Common Stock | Sale | -$3.75M | -200K | -1.9% | $18.77* | 10.3M | Jul 26, 2021 | See Footnotes | F2, F3 |
| transaction | ERAS | Common Stock | Purchase | $4.42M | +200K | +1.94% | $22.10* | 10.5M | Aug 10, 2021 | See Footnotes | F1, F2, F4, F5 |
| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Underlying Class | Amount | Exercise Price | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| holding | ERAS | Stock Option (right to buy) | 167K | Jul 26, 2021 | Common Stock | 167K | $5.81 | Direct | F6, F7 |
| Id | Content |
|---|---|
| F1 | Represents the weighted average purchase price of shares purchased in a series of open market transactions on the transaction date at prices ranging from $21.77 to $22.28 per share. The Reporting Persons undertake to provide, upon request by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the Issuer, full information regarding the number of shares purchased at each price. |
| F2 | Shares reported herein are held by Cormorant Global Healthcare Master Fund, LP (the "Master Fund"), Cormorant Private Healthcare Fund II, LP ("Fund II"), and a managed account (the "Account"). Cormorant Asset Management, LP ("Cormorant") serves as the investment manager of the Master Fund, Fund II, and the Account. Bihua Chen serves as manager of the general partner of Cormorant. Ms. Chen disclaims beneficial ownership of the shares reported herein except to the extent of her pecuniary interest therein, and the filing of this Form 4 shall not be construed as an admission that Ms. Chen is the beneficial owner of any such shares for purposes of Section 16(a) of the Securities Exchange Act of 1934 or for any other purpose. |
| F3 | Shares reported herein as sold on July 26, 2021 represent 200,000 shares sold by the Master Fund. This sale was matchable under Section 16(b) of the Securities Exchange Act of 1934, as amended, with a purchase of the Common Stock of the Issuer by the Master Fund on July 20, 2021. Ms. Chen and the Issuer have entered into an agreement under which she has remitted to the Issuer $553,000, which represents full payment of the disgorgeable profit arising from such transaction. |
| F4 | Shares reported herein as purchased on August 10, 2021 represent 200,000 shares purchased by the Master Fund. |
| F5 | Represents (i) 1,728,710 shares of Common Stock held by the Master Fund, (ii) 7,716,443 shares of Common Stock held by Fund II, and (iii) 110,400 shares of Common Stock held by the Account. |
| F6 | Stock option grant for 166,666 shares, 41,667 shares of which become exercisable on 3/16/2022 and 124,999 shares of which become exercisable thereafter in equal monthly installments through 3/16/2025. |
| F7 | Stock options granted to Ms. Chen, in her capacity as a director of the Issuer. |